Bone scans overstage prostate cancer at initial staging compared with PSMA PET

Reston, VA—Bone scans have been found to overstage prostate cancer at initial staging compared to prostate specific membrane antigen (PSMA) PET, according to new research published in the November issue of The Journal of Nuclear Medicine. The significant false-positive rate of metastases on bone scans means that definitive therapy for local disease may have been withheld from patients inappropriately. 

PSMA PET is more accurate than CT and bone scans for staging patients with prostate cancer and in recent years has become the standard imaging modality at initial staging. Nearly all prostate cancer trials have used CT and bone scans for staging, however, and the best way to apply those data to patients staged with PSMA PET remains unclear.

“Most research to date has focused on the increased sensitivity of PSMA PET versus conventional imaging such as bone scans and CT,” said Thomas Hope, MD, vice chair of clinical operations and strategy in the Department of Radiology and Director of Molecular Therapy at the University of California in San Francisco. “In this study, my colleagues and I took the opposite approach and looked at where PSMA PET was negative when bone scans were positive.”

The multicenter retrospective diagnostic study included 167 prostate cancer patients at various disease states who were imaged with bone scans and PSMA PET within 100 days. Each study was interpreted by three blinded readers. Using PSMA PET scans as the reference standard, researchers evaluated positive predictive value, negative predictive value, and specificity for bone scans as well as inter-reader reproducibility, positivity rate, uptake on PSMA PET, and number of lesions.

While the specificity of bone scans was found to be high and similar across disease states, the positive predictive value of bone scans at initial staging was found to be much lower than in the overall population. When compared to PSMA PET, more than half (57 percent) of bone scans at initial staging were found to contain false-positive metastases.

“Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease,” said Hope “These results bring into question how to apply data from clinical trials that are based on bone scans to patients who receive PSMA PET. Looking at the big picture, this study highlights the importance of understanding how test characteristics impact patient management.”

This study was made available online in August 2023.

The authors of “Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers” include Thomas A. Hope, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; Matthias Benz, Martin Allen-Auerbach, Pawan Gupta, and Jeremie Calais, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; Fei Jiang, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; Daniel Thompson, Roxana Juarez, and Miguel Hernandez Pampaloni, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; and Francesco Barbato and Wolfgang P. Fendler, Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany.

Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.